Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a percussive breathing machine help meds reach scarred lungs?

NCT ID NCT05366387

Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a device that delivers rapid puffs of air (intrapulmonary percussive ventilation) can help inhaled medication reach scarred lung areas in people with idiopathic pulmonary fibrosis (IPF). Nine participants inhaled a radioactive tracer with and without the device, and imaging measured how much reached fibrotic regions. The goal was to see if the technique is feasible and safe, not to treat the disease itself.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intrapulmonary percussive ventilation device and 99mTc-DTPA aerosol
What this could lead to
If successful, this could show a way to deliver inhaled drugs more effectively to damaged lung areas in IPF, potentially improving future treatments.
What could go wrong
This is a very small, early feasibility study with only 9 participants, so results may not apply widely. It measures aerosol deposition, not actual treatment benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9 people

The number who actually took part.

Started

Nov 2022

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of IPF according to 2018 ATS/ERS/JRS/ALAT guidelines * Affiliation to health insurance * Signed informed consent Exclusion Criteria: * Other chronic lung disease * Airflow obstruction (FEV1/FVC\<0.7) * History of congestive heart failure * History of IPF exacerbation * History of lung cancer * Chronic cough precluding aerosol delivery and radioprotection * Claustrophobia * 24h/24 oxygen therapy * Any acute lung disease * Any potentially transmissible lung infection * Current or possible pregnancy and breastfeeding * Contra-indications to IPV : Emphysema, recent barotrauma, pneumothorax, pneumomediastinum * History of pneumothorax or pneumomediastinum * Patient unable to hold a mouthpiece tightly * Patient under legal protection (guardianship, curatorship) * Contraindication to the administration of Technescan DTPA

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic pulmonary fibrosis

Contacts and locations

Locations

  • Pulmonology Department, University Hospital, Tours

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.